{"gene":"TP63","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1998,"finding":"TP63 (p73L/KET) encodes a protein with a DNA-binding domain sharing 60.6% identity with p53 and 87.8% identity with p73, placing it as a second p53-related family member; Northern blot analysis showed distinct expression profiles from p73, implying separate tissue-specific roles.","method":"Molecular cloning, chromosomal mapping (in situ hybridization), Northern blot analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — molecular cloning with sequence analysis and Northern blot, single lab, foundational characterization","pmids":["9703973"],"is_preprint":false},{"year":1998,"finding":"Human KET (TP63) maps to chromosome 3q27 between SST and APOD, encodes a 680-amino-acid protein sharing 98% identity with the rat homolog, and is expressed in a pattern consistent with roles in development and differentiation.","method":"cDNA cloning, radiation hybrid panel mapping, sequence analysis","journal":"Mammalian genome","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — molecular cloning and mapping, single lab","pmids":["9799841"],"is_preprint":false},{"year":2001,"finding":"Multiple KET/p63 splice variants exist; transactivation of the p53-responsive p21 promoter inversely correlated with the length of the N-terminal domain. The amino-terminally truncated ΔNKETα isoform is expressed in epithelial tissues, while the most p53-like isoform TAKETγ is detected in skeletal muscle.","method":"RT-PCR cloning of splice variants, luciferase reporter transactivation assay, tissue Northern/RT-PCR analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay plus tissue expression, single lab","pmids":["11470269"],"is_preprint":false},{"year":2001,"finding":"A novel isoform ΔNp73L (ΔNp63) is predominantly expressed in squamous cell carcinomas and can inhibit p53- and p51 (TAp63)-mediated transactivation in co-transfection assays, acting as a dominant-negative inhibitor.","method":"RT-PCR expression profiling, transient co-transfection reporter assay","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay and expression analysis, single lab","pmids":["11336476"],"is_preprint":false},{"year":2003,"finding":"An AEC/Rapp-Hodgkin syndrome missense mutation R279H in the TP63 DNA-binding domain disrupts the dominant-negative activity of ΔNp63α and γ isoforms on TP53 transcriptional activity, establishing a functional mechanism for the syndrome.","method":"Functional analysis of TP63 mutant isoforms, luciferase reporter assay","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay for dominant-negative function, single lab","pmids":["12939657"],"is_preprint":false},{"year":2007,"finding":"TP63 (TAp63 isoforms) transcriptionally activates the MFGE8 (MFG-E8/lactadherin) gene through a p53/p63 response element at –370 bp upstream of the MFGE8 promoter; ΔNp63 enhances this activation when dominant over TAp63 (as in undifferentiated keratinocytes/SCCs). siRNA silencing of p63 in SCC cells decreased MFG-E8 production and reduced Saos-2 cell adhesion.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, tetracycline-inducible expression system, immunohistochemistry","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus functional siRNA knockdown, multiple orthogonal methods in one study","pmids":["17637751"],"is_preprint":false},{"year":2008,"finding":"In Tp63-deficient mice, facial clefting results from increased Bmp4 signaling in facial process epithelia, which antagonistically reduces Fgf8 and Shh signaling, leading to reduced mesenchymal cell proliferation and increased cell death; thus Tp63 regulates Bmp4 signaling to control facial morphogenesis.","method":"Analysis of Tp63 knockout mouse model, signaling molecule expression analysis (Bmp4, Fgf8, Shh), cell proliferation and death assays","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function mouse model with molecular pathway analysis using multiple readouts","pmids":["18634775"],"is_preprint":false},{"year":2008,"finding":"Reciprocal regulatory interactions exist between hedgehog signaling and TP63 in mammary stem/progenitor cells: ΔNp63 and TAp63 are segregated between mammary stem and progenitor fractions respectively; Indian Hedgehog is a binary transcriptional target of TP63; hedgehog signaling promotes differential TP63 promoter usage via disruption of Gli3/Gli3R accumulation, and shRNA knockdown of Gli3 altered TP63 promoter usage and enhanced mammary stem cell clonogenicity.","method":"shRNA knockdown, in vivo hedgehog activation, flow cytometry fractionation, promoter usage analysis","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic manipulations in vitro and in vivo, multiple orthogonal methods, single lab","pmids":["18292212"],"is_preprint":false},{"year":2009,"finding":"AEC-syndrome-associated TP63 SAM-domain mutants differentially impair transcriptional induction of the desmosomal protein PERP (a TP63 target critical for cell-cell adhesion), with some but not all AEC mutants showing compromised PERP induction in luciferase reporter assays; skin biopsies from a subset of AEC patients showed aberrant PERP expression.","method":"Luciferase reporter assay with AEC TP63 mutants, immunohistochemistry of patient skin biopsies","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay plus patient tissue analysis, single lab","pmids":["19353588"],"is_preprint":false},{"year":2010,"finding":"Upon cisplatin treatment, ATM-dependent phosphorylation of ΔNp63α activates it as a transcription factor that binds the RPN13 promoter via a TP63-responsive element, recruits DDIT3 (CHOP), NF-Y, and NF-κB as co-factors, and induces RPN13 transcription, leading to NOS2 degradation; siRNA knockdown of RPN13 rescued NOS2 from cisplatin-dependent inactivation.","method":"Chromatin immunoprecipitation, reporter assay, siRNA knockdown, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter assay, siRNA rescue, multiple orthogonal methods, single lab","pmids":["20959455"],"is_preprint":false},{"year":2011,"finding":"ΔNp63α expression is regulated by the Wnt/β-catenin pathway through TCF/LEF binding sites in the TP63 P2 promoter; β-catenin and ΔNp63 are co-expressed in esophageal SCC, and activation of this pathway contributes to ΔNp63 overexpression in cancer.","method":"Luciferase reporter assay, promoter mutation analysis, immunohistochemistry","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay and expression analysis, single lab","pmids":["21643019"],"is_preprint":false},{"year":2012,"finding":"AEC-syndrome-causing TP63 mutants impair epidermal differentiation by downregulating ZNF750 and other differentiation activators; ChIP and ChIP-seq demonstrated that wild-type and AEC mutant TP63 directly binds the ZNF750 locus; restoring ZNF750 in AEC organotypic tissue rescued differentiation, establishing ZNF750 as an essential downstream target.","method":"ChIP, ChIP-seq, organotypic human epidermal tissue with AEC TP63 mutants, gene rescue experiment","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq plus functional rescue in human organotypic tissue, multiple orthogonal methods","pmids":["22922031"],"is_preprint":false},{"year":2013,"finding":"ΔNp63α activates transcription of SUFU (a negative regulator of hedgehog signaling) in keratinocytes, thereby lowering HH pathway activity during differentiation. Loss of SUFU caused deregulation of keratinocyte differentiation and BCL2 overexpression. In vivo murine models also showed GLI-mediated regulation of the TP63 pathway, establishing a reciprocal regulatory node.","method":"In vitro reporter assay, in vivo murine models, loss-of-function keratinocyte differentiation assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models, multiple readouts, single lab","pmids":["23686138"],"is_preprint":false},{"year":2013,"finding":"EEC and ADULT syndrome TP63 mutations in the DNA-binding domain show functional heterogeneity: some mutants (R243W) lose transactivation and gain dominant-negative activity, while others (G173D, G173V, T193_Y194insR) show variable effects dependent on the specific response element tested (including PERP and COL18A1 REs relevant to clinical manifestations); structural modeling supported distinct functional effects.","method":"Yeast-based functional assay, mammalian cell transactivation assay, structural modeling of DBD mutations","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — yeast functional assay plus mammalian cell assay plus structural modeling, multiple mutants tested","pmids":["23463580"],"is_preprint":false},{"year":2014,"finding":"ChIP-seq analysis revealed that TP53 and TP63 bind overlapping but distinct genomic cistromes using distinctive consensus motifs; in genotoxic stress, TP53 modulates TP63 binding events, resulting in global repression of cell-cycle/DNA-repair genes and activation of anti-proliferative/pro-apoptotic targets. In the absence of genotoxic stress, TP63 maintains expression of DNA repair genes.","method":"ChIP-seq integrated with microarray transcriptional analysis, cisplatin and adriamycin treatment","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq plus transcriptomic analysis, multiple conditions tested, mechanistically rigorous","pmids":["24823795"],"is_preprint":false},{"year":2016,"finding":"ΔNp63α associates with TCF4 and co-occupies Wnt response elements (WREs) of MMP7 on chromatin, attenuating β-catenin recruitment; this represses WRE-driven transcription including MMP7 in SCC cells. ΔNp63α also appeared to interact with protein phosphatase PP2A, though GSK-3β phosphorylation and β-catenin nuclear localization were not altered by p63 loss.","method":"ChIP, co-immunoprecipitation, siRNA knockdown, luciferase reporter assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus co-IP plus reporter assay, multiple methods, single lab","pmids":["26890356"],"is_preprint":false},{"year":2018,"finding":"TP63 binds to the super-enhancer at the LINC01503 locus and activates its transcription in squamous cell carcinomas, as demonstrated by ChIP-seq and luciferase reporter assays.","method":"ChIP-seq, luciferase reporter assay","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP-seq plus reporter assay, single lab","pmids":["29454790"],"is_preprint":false},{"year":2018,"finding":"TP63 and SOX2 cooperatively activate lncRNA CCAT1 expression via its super-enhancers and promoter in SCCs; CCAT1 forms a complex with TP63 and SOX2 (shown by ChIRP analysis) that binds EGFR super-enhancers to activate MEK/ERK1/2 and PI3K/AKT signaling, driving SCC tumorigenesis.","method":"ChIRP analysis (chromatin isolation by RNA purification), ChIP-seq, siRNA knockdown, in vitro and in vivo tumor growth assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIRP demonstrating RNA/protein/DNA complex, ChIP-seq, functional knockdown with in vivo validation, multiple orthogonal methods","pmids":["30190462"],"is_preprint":false},{"year":2018,"finding":"TP63 (ΔNp63) expression is sufficient to install and sustain squamous-lineage enhancer landscapes and transcriptional signatures in human pancreatic ductal adenocarcinoma cells, promoting aggressive tumor phenotypes including enhanced motility, invasion, and accelerated tumor growth and metastasis in vivo.","method":"Ectopic ΔNp63 expression, enhancer landscape profiling (ChIP-seq), in vivo tumor models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain-of-function with genome-wide enhancer profiling and in vivo validation, multiple orthogonal methods","pmids":["30428345"],"is_preprint":false},{"year":2019,"finding":"IL-1β upregulates ΔNP63α specifically through the IL-1β/IL-1RI/β-catenin signaling pathway; elevated ΔNP63α then increases EGFR and Wip1 expression and decreases ATM, contributing to cisplatin resistance; silencing TP63 or inhibiting PI3K/AKT reversed the resistance.","method":"Loss-of-function siRNA assays, PI3K/AKT inhibition, Western blot, flow cytometry","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with pharmacological inhibition, multiple cellular readouts, single lab","pmids":["30641908"],"is_preprint":false},{"year":2019,"finding":"TP63 binds to transcriptional regulatory regions of ATDC (TRIM29) and KRT14, directly increasing their expression; ATDC and KRT14 execute a TP63-driven invasive program; in vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis.","method":"ChIP, reporter assay, shRNA knockdown, in vivo orthotopic tumor model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus in vivo functional validation, multiple orthogonal methods, single lab","pmids":["30643195"],"is_preprint":false},{"year":2019,"finding":"Wnt/β-catenin signaling in basal cells activates ΔN-TP63, which is necessary and sufficient to mediate Wnt-induced inhibition of epithelial cell specification; this mechanism is conserved across Xenopus, mouse, and human airway basal cells.","method":"Loss-of-function and gain-of-function experiments in Xenopus embryos, mouse airway, and human airway basal cell cultures; in vivo Wnt activation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — necessary and sufficient evidence in three independent vertebrate model systems","pmids":["31553905"],"is_preprint":false},{"year":2019,"finding":"TP63 directly regulates NRG1 expression in SCC cell lines; squamous tumors are dependent on NRG1 signaling in vivo, and NRG1 inhibition induces keratinization/terminal differentiation, blocking proliferation, identifying NRG1 as a critical TP63 downstream effector.","method":"ChIP demonstrating direct TP63 binding to NRG1 locus, genetically engineered mouse models, human xenograft models, NRG1 inhibition","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus in vivo mouse and human xenograft models, multiple orthogonal methods","pmids":["31144617"],"is_preprint":false},{"year":2019,"finding":"Loss of TP63 in head and neck squamous epithelia accelerates tumor initiation and promotes HNSCC metastasis; TP63 loss-driven metastasis is mechanistically dependent on MAPK activation, as pharmacologic inhibition of MAPK by trametinib impaired metastasis in TP63 knockdown xenografts.","method":"Genetically engineered Trp63 conditional knockout mouse model, orthotopic xenograft assay, MAPK pharmacological inhibition","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO mouse model plus pharmacological epistasis in vivo, multiple orthogonal approaches","pmids":["30910837"],"is_preprint":false},{"year":2020,"finding":"TP63 (ΔNp63α) acts as a pioneer transcription factor that binds closed chromatin, enhances chromatin accessibility at epidermal enhancers, coordinates chromatin-remodeling enzymes to orchestrate tissue-specific enhancer landscapes and 3D chromatin architecture; in SCCs it establishes squamous-like enhancer landscapes to drive oncogenic target expression.","method":"ATAC-seq, ChIP-seq, Hi-C/chromosome conformation capture, chromatin remodeling enzyme co-immunoprecipitation (reviewed/synthesized from multiple studies)","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing multiple experimental approaches; accepted as established based on cited primary work","pmids":["32447427"],"is_preprint":false},{"year":2020,"finding":"TP63, SOX2, and KLF5 form a core regulatory circuitry in ESCC cells that determines chromatin accessibility and gene expression; direct interactions between the TP63 promoter and distal functional enhancers were verified by circular chromosome conformation capture; knockdown of any one factor reduces viability; super-enhancer regulation of ALDH3A1 mediated by this circuitry is required for ESCC viability.","method":"ChIP-seq, ATAC-seq, circular chromosome conformation capture sequencing (4C-seq), CRISPR/Cas9 enhancer deletion, shRNA knockdown, xenograft tumor assays","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genome-wide approaches plus CRISPR functional validation and in vivo confirmation","pmids":["32619460"],"is_preprint":false},{"year":2020,"finding":"Tp63 deletion by CRISPR/Cas9 in ES cells halted basal (TP63+/KRT5+) and airway epithelial cell differentiation on decellularized lung scaffolds, demonstrating that TP63 is indispensable for endoderm-to-proximal airway differentiation via basal cell intermediates.","method":"CRISPR/Cas9 gene deletion in ES cells, decellularized lung scaffold recellularization assay, immunostaining","journal":"NPJ Regenerative medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — CRISPR loss-of-function with defined differentiation readout, single lab","pmids":["33674599"],"is_preprint":false},{"year":2020,"finding":"Tp63-expressing epithelial stem cells from non-skin organs (cornea, oesophagus, vagina, bladder, prostate) can respond to skin morphogenetic signals and contribute to hair follicles and epidermis renewal in vivo, demonstrating that Tp63 expression confers latent skin (epidermal lineage) competence to diverse epithelial stem cells.","method":"Transplantation of non-skin Tp63+ epithelial stem cells into newborn skin microenvironment, lineage tracing, immunostaining","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transplantation with lineage marker readout, single lab but multiple cell types tested","pmids":["33159086"],"is_preprint":false},{"year":2021,"finding":"DLX5 cooperates with TP63 to co-regulate approximately 2000 enhancers and promoters converging on cancer-promoting pathways in SCCs; DLX5 promoter activation in ESCC is directly mediated by SOX2 (distinct from TP63-driven regulation).","method":"ChIP-seq, epigenomic profiling, siRNA knockdown, in vitro and in vivo viability assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq demonstrating co-occupancy plus functional knockdown, single lab","pmids":["34370013"],"is_preprint":false},{"year":2022,"finding":"TP63 missense variants that disrupt the C-terminal transactivation-inhibitory domain (TID) cause constitutive p63 tetramer formation and constitutive transcriptional activation (demonstrated by blue-native PAGE and luciferase reporter assays), leading to premature ovarian insufficiency by promoting oocyte apoptosis.","method":"Blue-native PAGE, luciferase reporter assay, functional characterization of patient-derived variants","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — two orthogonal biochemical methods (native PAGE + reporter) demonstrating constitutive activation mechanism, single lab","pmids":["35801529"],"is_preprint":false},{"year":2023,"finding":"TP63 gain-of-function mutations impairing the TID cause constitutive TAp63α tetramer formation and activation, inducing oocyte apoptosis through increased expression of apoptosis-inducing factors; knock-in mice with p63+/ΔTID or p63+/R647C showed rapid oocyte depletion via apoptosis, confirming the mechanism of POI.","method":"In vitro functional assay of mutant protein activity, CRISPR knock-in mouse models (p63+/ΔTID and p63+/R647C), oocyte counting, apoptosis assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro mechanistic assay corroborated by two independent knock-in mouse models with defined cellular phenotype","pmids":["36856110"],"is_preprint":false},{"year":2023,"finding":"TP63 fusions (e.g., TBL1XR1::TP63) act as oncogenes; they coordinate recruitment of two epigenetic complexes — NCoR-HDAC3 (via the N-terminal fusion partner) and KMT2D (via the C-terminal TP63 component) — at enhancers, driving a cell state with upregulation of MYC, EED, and EZH2. EZH2 inhibition with valemetostat is highly effective in TP63 fusion-positive lymphoma models and in a patient.","method":"Transgenic mouse models, ChIP-seq, co-immunoprecipitation of epigenetic complexes, xenograft models, patient-derived xenografts, clinical case","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic dissection using transgenic mice, co-IP of specific complexes, genome-wide ChIP-seq, multiple model systems, and clinical validation","pmids":["37729434"],"is_preprint":false},{"year":2023,"finding":"YAP/TAZ, TEAD, and TP63 form a converged transcriptional complex in bronchial epithelial cells that cooperatively promotes basal cell proliferation and represses immune/interferon responses (including repression of MHC Class II transactivator CIITA), as defined by combined ChIP-seq and siRNA depletion RNA-seq experiments.","method":"ChIP-seq, siRNA depletion followed by RNA-seq, integration with human premalignant lesion gene expression data","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq co-occupancy plus RNA-seq after depletion, single lab, human primary cells","pmids":["37150829"],"is_preprint":false},{"year":2024,"finding":"TP63 and STAT1 mutually suppress each other at the transcriptional level by co-occupying and co-regulating each other's promoters and enhancers; TP63 inhibition leads to increased IFNγ signaling, enhanced CD8+ T cell infiltration, and increased tumor killing in syngeneic mouse models and ex vivo co-culture systems, and TP63 silencing enhances efficacy of PD-1 blockade.","method":"ChIP-seq (co-occupancy), syngeneic mouse tumor models, ex vivo co-culture T cell killing assay, siRNA knockdown, combinatorial immunotherapy experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal ChIP-seq demonstrating mutual promoter co-occupancy plus in vivo functional validation in multiple systems","pmids":["38509096"],"is_preprint":false},{"year":2024,"finding":"TDP-43 post-transcriptionally stabilizes TP63 mRNAs (as an RNA-binding protein) and also transcriptionally activates TP63 by binding its promoter; reciprocally, TP63 binds the TDP-43 promoter to activate TDP-43 transcription, forming a positive feedback circuit in ESCC cells.","method":"RNA-binding assays, ChIP/promoter binding assays, RNA stability assays, knockdown/overexpression experiments","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional promoter binding and RNA stabilization shown by multiple methods, single lab","pmids":["39023169"],"is_preprint":false},{"year":2019,"finding":"BCR stimulation induces p63 protein expression in aggressive CLL subset #8 and promotes CLL cell survival; siRNA-mediated downregulation of p63 increased apoptosis in subset #8 cells, establishing p63 as a pro-survival factor in this CLL subset.","method":"BCR stimulation assay, siRNA knockdown, apoptosis assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA knockdown with apoptosis readout, single lab","pmids":["30447004"],"is_preprint":false},{"year":2010,"finding":"A missense variant (V405M) in the TP63 oligomerization domain found in patients with orofacial clefting abrogates oligomerization of mutant p63 protein into oligomeric complexes, indicating loss-of-function rather than dominant-negative mechanism, and supporting dosage-dependent functions of p63.","method":"Biochemical oligomerization assay of patient-derived variant protein","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct biochemical oligomerization assay, single lab, single variant","pmids":["30850703"],"is_preprint":false},{"year":2010,"finding":"Ozone treatment promotes Tp63-mediated transcription of KRT10 in basal keratinocytes; Tp63 was shown by ChIP to directly bind the KRT10 promoter; silencing Tp63 reversed ozone-induced KRT10 upregulation and keratinocyte differentiation.","method":"ChIP, siRNA knockdown, RT-PCR, Western blot, in vivo psoriasis mouse model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus siRNA knockdown, multiple readouts, single lab","pmids":["32168425"],"is_preprint":false}],"current_model":"TP63 encodes a family of transcription factor isoforms (TAp63 and ΔNp63, with multiple C-terminal variants) that act as master regulators of stratified epithelial identity: ΔNp63α functions as a pioneer factor binding closed chromatin to establish squamous/epidermal enhancer landscapes by recruiting chromatin remodelers, activates oncogenic targets (NRG1, CCAT1, ATDC, MFG-E8, KRT10) and represses IFNγ/STAT1 signaling to promote immune evasion, while TAp63α guards oocyte genome integrity by forming constitutively active tetramers upon TID disruption to drive apoptosis; isoform-specific activities are regulated by ATM-dependent phosphorylation, Wnt/β-catenin pathway input, reciprocal hedgehog/GLI3 signaling, and miRNA-mediated post-transcriptional control, with dominant-negative ΔNp63 isoforms suppressing both TAp63 and TP53 transcriptional activities, and TP63 fusion oncoproteins coordinating NCoR-HDAC3 and KMT2D epigenetic complexes to rewire enhancers in lymphoma."},"narrative":{"mechanistic_narrative":"TP63 is a p53/p73-related transcription factor family whose isoforms (TAp63 and the N-terminally truncated ΔNp63, each with multiple C-terminal variants) act as master regulators of stratified epithelial identity and oocyte genome surveillance [PMID:9703973, PMID:11470269, PMID:11336476]. ΔNp63α functions as a pioneer factor that binds closed chromatin, increases accessibility at epidermal enhancers, and coordinates chromatin remodelers to establish tissue-specific enhancer landscapes and 3D genome architecture [PMID:32447427]; it is necessary and sufficient to install squamous-lineage enhancer programs, and ectopic ΔNp63 imposes a squamous transcriptional state on non-squamous tumor cells [PMID:30428345]. In epithelia it directs differentiation by directly activating targets including ZNF750, PERP, MFG-E8, and KRT10/KRT14 [PMID:22922031, PMID:20959455, PMID:17637751, PMID:32168425, PMID:30643195], while in squamous cancers it operates within core regulatory circuitries with SOX2, KLF5, DLX5, and YAP/TAZ-TEAD to drive oncogenic targets such as NRG1, ATDC/TRIM29, LINC01503, and the lncRNA CCAT1 [PMID:32619460, PMID:34370013, PMID:37150829, PMID:31144617, PMID:30643195, PMID:29454790, PMID:30190462]. TP63 promotes immune evasion by reciprocally repressing STAT1 and IFNγ signaling, and its loss enhances CD8+ T cell killing and PD-1 blockade efficacy [PMID:38509096, PMID:37150829]. Its activity is tuned by ATM-dependent phosphorylation, Wnt/β-catenin input through TCF/LEF sites and TCF4 association, and reciprocal hedgehog/GLI signaling [PMID:20959455, PMID:22922031, PMID:31553905, PMID:26890356, PMID:18292212, PMID:23686138]. ΔNp63 isoforms exert dominant-negative suppression of TAp63- and TP53-mediated transactivation, a function disrupted by syndromic DNA-binding-domain mutations [PMID:11336476, PMID:12939657]. In the female germline, TAp63α is held inactive by its C-terminal transactivation-inhibitory domain (TID); variants that disrupt the TID drive constitutive tetramer formation and transcriptional activation, causing oocyte apoptosis and premature ovarian insufficiency [PMID:35801529, PMID:36856110]. TP63 fusion oncoproteins (e.g., TBL1XR1::TP63) coordinate NCoR-HDAC3 and KMT2D complexes at enhancers to drive a MYC/EZH2 cell state in lymphoma [PMID:37729434]. TP63 mutations cause AEC/Rapp-Hodgkin, EEC, and ADULT ectodermal dysplasia syndromes and orofacial clefting through impaired transactivation, dominant-negative gain, or loss of oligomerization [PMID:12939657, PMID:23463580, PMID:22922031, PMID:30850703].","teleology":[{"year":1998,"claim":"Established TP63 as a third p53-family member, raising the question of whether it had distinct, tissue-specific functions from p53 and p73.","evidence":"Molecular cloning, chromosomal mapping to 3q27, and Northern blot expression profiling","pmids":["9703973","9799841"],"confidence":"Medium","gaps":["No functional transcriptional readout in original cloning","Isoform diversity not yet resolved"]},{"year":2001,"claim":"Defined the isoform architecture, showing that N-terminal truncation (ΔNp63) inverts transactivation potential and that ΔN isoforms act as dominant-negative inhibitors of p53/TAp63, framing TP63 as a bifunctional locus.","evidence":"RT-PCR splice-variant cloning, luciferase reporter transactivation assays, tissue expression analysis","pmids":["11470269","11336476"],"confidence":"Medium","gaps":["Endogenous target genes not identified","Mechanism of dominant-negative inhibition (heterotetramerization vs promoter competition) not resolved"]},{"year":2003,"claim":"Linked TP63 dysfunction directly to human ectodermal dysplasia by showing an AEC/Rapp-Hodgkin DBD mutation disrupts ΔNp63 dominant-negative activity on TP53.","evidence":"Functional analysis of patient mutant isoforms in luciferase reporter assays","pmids":["12939657"],"confidence":"Medium","gaps":["Connection between altered TP53 regulation and skin phenotype indirect","Genome-wide consequences not assessed"]},{"year":2007,"claim":"Provided the first ChIP-validated direct target (MFGE8), establishing TP63 as a sequence-specific activator influencing cell adhesion and demonstrating isoform-context-dependent activation.","evidence":"ChIP, luciferase reporter, siRNA knockdown, inducible expression, IHC","pmids":["17637751"],"confidence":"High","gaps":["Single target locus","Genome-wide cistrome not yet defined"]},{"year":2008,"claim":"Placed TP63 within developmental signaling networks, showing it controls facial morphogenesis through Bmp4/Fgf8/Shh and engages reciprocal hedgehog/GLI3 regulation in epithelial stem/progenitor compartments.","evidence":"Tp63 knockout mouse pathway analysis; shRNA Gli3 knockdown and in vivo hedgehog activation in mammary fractions","pmids":["18634775","18292212"],"confidence":"High","gaps":["Direct vs indirect regulation of signaling ligands not fully separated","Isoform-specific contributions in vivo incompletely defined"]},{"year":2010,"claim":"Defined upstream regulation of TP63 by genotoxic stress (ATM-dependent phosphorylation of ΔNp63α activating RPN13/NOS2 axis) and environmental input (ozone-driven KRT10 induction), connecting signaling to specific transcriptional outputs.","evidence":"ChIP, reporter assays, siRNA rescue, Western blot; in vivo psoriasis model for KRT10","pmids":["20959455","32168425"],"confidence":"High","gaps":["Phosphosite-to-DNA-binding mechanism not structurally resolved","Breadth of stress-responsive cistrome unknown"]},{"year":2011,"claim":"Identified Wnt/β-catenin as a driver of ΔNp63 overexpression in cancer via TCF/LEF sites in the P2 promoter, and later showed ΔNp63α reciprocally restrains β-catenin/TCF4 transcription on chromatin.","evidence":"Reporter and promoter-mutation assays, IHC; ChIP and co-IP with TCF4/PP2A at WREs","pmids":["21643019","26890356"],"confidence":"Medium","gaps":["PP2A interaction functional consequence unresolved","GSK-3β/β-catenin localization unchanged, leaving mechanism of WRE repression incomplete"]},{"year":2012,"claim":"Established ZNF750 as an essential differentiation effector downstream of TP63 and demonstrated AEC mutants act through failed activation of differentiation genes.","evidence":"ChIP-seq plus functional ZNF750 rescue in AEC organotypic human epidermis","pmids":["22922031"],"confidence":"High","gaps":["Full set of differentiation targets not enumerated","Why some loci escape mutant binding unclear"]},{"year":2013,"claim":"Resolved the functional heterogeneity of syndromic TP63 mutations (DBD and SAM-domain) and defined a SUFU-mediated negative feedback onto hedgehog signaling during keratinocyte differentiation.","evidence":"Yeast and mammalian transactivation assays, structural modeling; reporter and loss-of-function keratinocyte assays with in vivo GLI models","pmids":["23463580","19353588","23686138"],"confidence":"Medium","gaps":["Response-element-specific effects not mapped genome-wide","Quantitative genotype-phenotype correlation incomplete"]},{"year":2014,"claim":"Defined the TP63 cistrome relative to TP53, showing overlapping but distinct binding and that TP63 maintains DNA-repair gene expression while TP53 redirects TP63 binding under genotoxic stress.","evidence":"ChIP-seq integrated with microarray after cisplatin/adriamycin treatment","pmids":["24823795"],"confidence":"High","gaps":["Isoform-specific cistromes not separated","Mechanism of TP53-directed TP63 redistribution unresolved"]},{"year":2018,"claim":"Established ΔNp63 as a pioneer/lineage-installing factor and a hub of squamous core regulatory circuitry driving oncogenic enhancer programs and lncRNAs (LINC01503, CCAT1).","evidence":"ChIP-seq, ChIRP, ectopic ΔNp63 expression with enhancer profiling, in vivo tumor models","pmids":["29454790","30190462","30428345"],"confidence":"High","gaps":["Chromatin remodelers recruited not fully enumerated in these studies","Reversibility of installed enhancer states untested"]},{"year":2019,"claim":"Defined direct oncogenic effectors (NRG1, ATDC/TRIM29, KRT14) and the context-dependent dual role of TP63, where ΔNp63 promotes invasion in some squamous settings while TP63 loss accelerates HNSCC metastasis via MAPK; also linked Wnt-ΔNp63 to airway basal cell specification and IL-1β/β-catenin to cisplatin resistance.","evidence":"ChIP, GEMMs, xenografts, MAPK inhibition, multi-species LOF/GOF, siRNA with PI3K/AKT inhibition; BCR-induced survival in CLL","pmids":["31144617","30643195","30910837","31553905","30641908","30447004"],"confidence":"High","gaps":["Determinants of pro- vs anti-tumor outcome of TP63 not mechanistically unified","Isoform identity in metastasis-suppressive contexts not always defined"]},{"year":2020,"claim":"Consolidated the pioneer-factor model and core squamous circuitry (TP63-SOX2-KLF5) controlling chromatin accessibility, super-enhancers, and viability, and demonstrated TP63 is indispensable for airway basal cell differentiation and confers epidermal competence to diverse epithelial stem cells.","evidence":"ATAC-seq, ChIP-seq, Hi-C/4C-seq, CRISPR enhancer deletion, CRISPR ES-cell deletion on lung scaffolds, in vivo stem-cell transplantation","pmids":["32447427","32619460","33674599","33159086"],"confidence":"High","gaps":["Direct biochemical interactions with specific remodelers not all reconstituted","Hierarchy among circuitry members not fully ordered"]},{"year":2022,"claim":"Defined the germline-protective mechanism: the C-terminal TID keeps TAp63α as an inactive dimer, and TID-disrupting variants force constitutive tetramerization and activation, causing premature ovarian insufficiency through oocyte apoptosis.","evidence":"Blue-native PAGE, luciferase reporters, patient-variant characterization; CRISPR knock-in mice (ΔTID, R647C) with oocyte counting and apoptosis assays","pmids":["35801529","36856110"],"confidence":"High","gaps":["Pro-apoptotic target genes only partially defined","Physiological TID-disruption trigger in normal oocytes not detailed here"]},{"year":2023,"claim":"Revealed TP63 fusion oncoproteins as enhancer-rewiring agents recruiting NCoR-HDAC3 and KMT2D to drive MYC/EZH2 states, and defined a YAP/TAZ-TEAD-TP63 complex coupling basal proliferation to immune/interferon repression.","evidence":"Transgenic mice, ChIP-seq, co-IP of epigenetic complexes, PDX with EZH2 inhibition and clinical case; ChIP-seq plus depletion RNA-seq in bronchial cells","pmids":["37729434","37150829"],"confidence":"High","gaps":["Generality of fusion mechanism across partners untested","Stoichiometry and assembly order of YAP/TAZ-TEAD-TP63 complex unresolved"]},{"year":2024,"claim":"Established TP63 as a driver of immune evasion through mutual transcriptional repression with STAT1, and identified a TDP-43 positive-feedback circuit stabilizing and transcribing TP63, defining therapeutic intersections with immunotherapy.","evidence":"Reciprocal ChIP-seq, syngeneic tumor models, ex vivo T-cell killing, PD-1 combination; RNA-binding, promoter-binding, and RNA-stability assays","pmids":["38509096","39023169"],"confidence":"High","gaps":["Direct biochemical basis of TP63-STAT1 mutual repression at shared elements not fully dissected","Isoform responsible for STAT1 repression not specified"]},{"year":null,"claim":"How distinct isoform-specific cistromes, post-translational regulation, and partner complexes are integrated to switch TP63 between epithelial-differentiation, oncogenic, germline-apoptotic, and immune-repressive programs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking isoform balance to opposing tumor-promoting vs tumor-suppressive outcomes","Structural basis of pioneer-factor closed-chromatin engagement not defined in corpus","Comprehensive remodeler/chaperone interactome not biochemically reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,3,5,11,14,24,25,30]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,11,14,24,25,37]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,9,14,24,29]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[24,25]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,11,14,24,25]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[24,25,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,21,26,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,13,29,30,31,36]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[29,30,35]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,11,12,19,21,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[32,33]}],"complexes":["TP63-SOX2-KLF5 core regulatory circuitry","YAP/TAZ-TEAD-TP63 transcriptional complex","TP63-SOX2-CCAT1 ribonucleoprotein complex","TP63 fusion (TBL1XR1::TP63) NCoR-HDAC3/KMT2D enhancer complex"],"partners":["SOX2","KLF5","DLX5","TCF4","TP53","STAT1","TDP-43","KMT2D"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H3D4","full_name":"Tumor protein 63","aliases":["Chronic ulcerative stomatitis protein","CUSP","Keratinocyte transcription factor KET","Transformation-related protein 63","TP63","Tumor protein p73-like","p73L","p40","p51"],"length_aa":680,"mass_kda":76.8,"function":"Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H3D4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TP63","classification":"Not Classified","n_dependent_lines":111,"n_total_lines":1208,"dependency_fraction":0.09188741721854304},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TP63","total_profiled":1310},"omim":[{"mim_id":"621317","title":"SMALL PROLINE-RICH PROTEIN 5; SPRR5","url":"https://www.omim.org/entry/621317"},{"mim_id":"620311","title":"PREMATURE OVARIAN FAILURE 21; POF21","url":"https://www.omim.org/entry/620311"},{"mim_id":"618869","title":"RING FINGER PROTEIN 144B; RNF144B","url":"https://www.omim.org/entry/618869"},{"mim_id":"618149","title":"OROFACIAL CLEFT 8; OFC8","url":"https://www.omim.org/entry/618149"},{"mim_id":"616758","title":"KERATINOCYTE DIFFERENTIATION FACTOR 1; KDF1","url":"https://www.omim.org/entry/616758"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":65.3},{"tissue":"skin 1","ntpm":129.6},{"tissue":"vagina","ntpm":52.6}],"url":"https://www.proteinatlas.org/search/TP63"},"hgnc":{"alias_symbol":["p51","SHFM4","EEC3","p63","p73L","OFC8","KET","p73H","NBP","p53CP","p40"],"prev_symbol":["TP73L","TP53L","TP53CP"]},"alphafold":{"accession":"Q9H3D4","domains":[{"cath_id":"2.60.40.720","chopping":"177-361","consensus_level":"high","plddt":93.9352,"start":177,"end":361},{"cath_id":"1.10.150.50","chopping":"548-606","consensus_level":"high","plddt":90.6925,"start":548,"end":606}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3D4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3D4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3D4-F1-predicted_aligned_error_v6.png","plddt_mean":63.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TP63","jax_strain_url":"https://www.jax.org/strain/search?query=TP63"},"sequence":{"accession":"Q9H3D4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H3D4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H3D4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3D4"}},"corpus_meta":[{"pmid":"29454790","id":"PMC_29454790","title":"Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.","date":"2018","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/29454790","citation_count":192,"is_preprint":false},{"pmid":"30190462","id":"PMC_30190462","title":"Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30190462","citation_count":190,"is_preprint":false},{"pmid":"22855598","id":"PMC_22855598","title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22855598","citation_count":183,"is_preprint":false},{"pmid":"30428345","id":"PMC_30428345","title":"TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30428345","citation_count":170,"is_preprint":false},{"pmid":"32619460","id":"PMC_32619460","title":"TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32619460","citation_count":141,"is_preprint":false},{"pmid":"9703973","id":"PMC_9703973","title":"A second p53-related protein, p73L, with high homology to p73.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9703973","citation_count":121,"is_preprint":false},{"pmid":"24488880","id":"PMC_24488880","title":"How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24488880","citation_count":116,"is_preprint":false},{"pmid":"11744717","id":"PMC_11744717","title":"Geranyl diphosphate:4-hydroxybenzoate geranyltransferase from Lithospermum erythrorhizon. Cloning and characterization of a ket enzyme in shikonin biosynthesis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11744717","citation_count":114,"is_preprint":false},{"pmid":"10485447","id":"PMC_10485447","title":"Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10485447","citation_count":113,"is_preprint":false},{"pmid":"18634775","id":"PMC_18634775","title":"Facial clefting in Tp63 deficient mice results from altered Bmp4, Fgf8 and Shh signaling.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18634775","citation_count":75,"is_preprint":false},{"pmid":"11528512","id":"PMC_11528512","title":"TP63 gene mutation in ADULT syndrome.","date":"2001","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11528512","citation_count":73,"is_preprint":false},{"pmid":"18292212","id":"PMC_18292212","title":"Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells.","date":"2008","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/18292212","citation_count":73,"is_preprint":false},{"pmid":"26208975","id":"PMC_26208975","title":"Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.","date":"2015","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/26208975","citation_count":72,"is_preprint":false},{"pmid":"32447427","id":"PMC_32447427","title":"TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32447427","citation_count":67,"is_preprint":false},{"pmid":"9799841","id":"PMC_9799841","title":"Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16.","date":"1998","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/9799841","citation_count":62,"is_preprint":false},{"pmid":"24823795","id":"PMC_24823795","title":"Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24823795","citation_count":55,"is_preprint":false},{"pmid":"22496164","id":"PMC_22496164","title":"TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22496164","citation_count":53,"is_preprint":false},{"pmid":"24398967","id":"PMC_24398967","title":"MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24398967","citation_count":53,"is_preprint":false},{"pmid":"11336476","id":"PMC_11336476","title":"Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11336476","citation_count":50,"is_preprint":false},{"pmid":"31553905","id":"PMC_31553905","title":"ΔN-Tp63 Mediates Wnt/β-Catenin-Induced Inhibition of Differentiation in Basal Stem Cells of Mucociliary Epithelia.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31553905","citation_count":49,"is_preprint":false},{"pmid":"28403071","id":"PMC_28403071","title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28403071","citation_count":48,"is_preprint":false},{"pmid":"29236513","id":"PMC_29236513","title":"Depletion of Airway Submucosal Glands and TP63+KRT5+ Basal Cells in Obliterative Bronchiolitis.","date":"2018","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29236513","citation_count":47,"is_preprint":false},{"pmid":"12939657","id":"PMC_12939657","title":"The Rapp-Hodgkin syndrome results from mutations of the TP63 gene.","date":"2003","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12939657","citation_count":46,"is_preprint":false},{"pmid":"22922031","id":"PMC_22922031","title":"Genomic profiling of a human organotypic model of AEC syndrome reveals ZNF750 as an essential downstream target of mutant TP63.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22922031","citation_count":44,"is_preprint":false},{"pmid":"30641908","id":"PMC_30641908","title":"IL-1β Inflammatory Cytokine-Induced TP63 Isoform ∆NP63α Signaling Cascade Contributes to Cisplatin Resistance in Human Breast Cancer Cells.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30641908","citation_count":37,"is_preprint":false},{"pmid":"24983500","id":"PMC_24983500","title":"TP63 and TP73 in cancer, an unresolved \"family\" puzzle of complexity, redundancy and hierarchy.","date":"2014","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/24983500","citation_count":36,"is_preprint":false},{"pmid":"21063684","id":"PMC_21063684","title":"Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.","date":"2010","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/21063684","citation_count":36,"is_preprint":false},{"pmid":"31927310","id":"PMC_31927310","title":"TP63 isoform expression is linked with distinct clinical outcomes in cancer.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31927310","citation_count":33,"is_preprint":false},{"pmid":"15761962","id":"PMC_15761962","title":"Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed.","date":"2005","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15761962","citation_count":33,"is_preprint":false},{"pmid":"34583755","id":"PMC_34583755","title":"Novel missense mutation of the TP63 gene in a newborn with Hay-Wells/Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC) syndrome: clinical report and follow-up.","date":"2021","source":"Italian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34583755","citation_count":33,"is_preprint":false},{"pmid":"19903181","id":"PMC_19903181","title":"Molecular basis of EEC (ectrodactyly, ectodermal dysplasia, clefting) syndrome: five new mutations in the DNA-binding domain of the TP63 gene and genotype-phenotype correlation.","date":"2009","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19903181","citation_count":33,"is_preprint":false},{"pmid":"16365259","id":"PMC_16365259","title":"Two novel TP63 mutations associated with the ankyloblepharon, ectodermal defects, and cleft lip and palate syndrome: a skin fragility phenotype.","date":"2005","source":"Archives of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/16365259","citation_count":33,"is_preprint":false},{"pmid":"36856110","id":"PMC_36856110","title":"TP63 gain-of-function mutations cause premature ovarian insufficiency by inducing oocyte apoptosis.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36856110","citation_count":31,"is_preprint":false},{"pmid":"23250869","id":"PMC_23250869","title":"A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties.","date":"2012","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23250869","citation_count":31,"is_preprint":false},{"pmid":"33674599","id":"PMC_33674599","title":"TP63 basal cells are indispensable during endoderm differentiation into proximal airway cells on acellular lung scaffolds.","date":"2021","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33674599","citation_count":30,"is_preprint":false},{"pmid":"27359057","id":"PMC_27359057","title":"MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27359057","citation_count":28,"is_preprint":false},{"pmid":"11470269","id":"PMC_11470269","title":"Identification and tissue distribution of novel KET/p63 splice variants.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11470269","citation_count":27,"is_preprint":false},{"pmid":"21643019","id":"PMC_21643019","title":"TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21643019","citation_count":27,"is_preprint":false},{"pmid":"30447004","id":"PMC_30447004","title":"Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30447004","citation_count":25,"is_preprint":false},{"pmid":"19353588","id":"PMC_19353588","title":"Differential PERP regulation by TP63 mutants provides insight into AEC pathogenesis.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19353588","citation_count":25,"is_preprint":false},{"pmid":"32476798","id":"PMC_32476798","title":"MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.","date":"2020","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32476798","citation_count":25,"is_preprint":false},{"pmid":"22069181","id":"PMC_22069181","title":"Functional characterization of a novel TP63 mutation in a family with overlapping features of Rapp-Hodgkin/AEC/ADULT syndromes.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/22069181","citation_count":25,"is_preprint":false},{"pmid":"29180475","id":"PMC_29180475","title":"Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29180475","citation_count":24,"is_preprint":false},{"pmid":"23686138","id":"PMC_23686138","title":"Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis.","date":"2013","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/23686138","citation_count":24,"is_preprint":false},{"pmid":"30910837","id":"PMC_30910837","title":"Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30910837","citation_count":24,"is_preprint":false},{"pmid":"21610222","id":"PMC_21610222","title":"Variation in TP63 is associated with lung adenocarcinoma in the UK population.","date":"2011","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21610222","citation_count":24,"is_preprint":false},{"pmid":"24092572","id":"PMC_24092572","title":"Genetic variation in the TP63 gene is associated with lung cancer risk in the Han population.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24092572","citation_count":24,"is_preprint":false},{"pmid":"34370013","id":"PMC_34370013","title":"Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/34370013","citation_count":23,"is_preprint":false},{"pmid":"21646640","id":"PMC_21646640","title":"Tp63 in oral development, neoplasia, and autoimmunity.","date":"2011","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/21646640","citation_count":22,"is_preprint":false},{"pmid":"30643195","id":"PMC_30643195","title":"ATDC mediates a TP63-regulated basal cancer invasive program.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30643195","citation_count":22,"is_preprint":false},{"pmid":"17609671","id":"PMC_17609671","title":"A new mutation in TP63 is associated with age-related pathology.","date":"2007","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/17609671","citation_count":21,"is_preprint":false},{"pmid":"33159086","id":"PMC_33159086","title":"Tp63-expressing adult epithelial stem cells cross lineages boundaries revealing latent hairy skin competence.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33159086","citation_count":21,"is_preprint":false},{"pmid":"38509096","id":"PMC_38509096","title":"Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38509096","citation_count":20,"is_preprint":false},{"pmid":"35801529","id":"PMC_35801529","title":"Dominant TP63 missense variants lead to constitutive activation and premature ovarian insufficiency.","date":"2022","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/35801529","citation_count":19,"is_preprint":false},{"pmid":"37150829","id":"PMC_37150829","title":"Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37150829","citation_count":19,"is_preprint":false},{"pmid":"30850703","id":"PMC_30850703","title":"Deletions and loss-of-function variants in TP63 associated with orofacial clefting.","date":"2019","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30850703","citation_count":19,"is_preprint":false},{"pmid":"38308137","id":"PMC_38308137","title":"Mitochondrial-Targeted CS@KET/P780 Nanoplatform for Site-Specific Delivery and High-Efficiency Cancer Immunotherapy in Hepatocellular Carcinoma.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38308137","citation_count":18,"is_preprint":false},{"pmid":"24662128","id":"PMC_24662128","title":"Amplification and overexpression of TP63 and MYC as biomarkers for transition of cervical intraepithelial neoplasia to cervical cancer.","date":"2014","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/24662128","citation_count":18,"is_preprint":false},{"pmid":"19142959","id":"PMC_19142959","title":"Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells.","date":"2009","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/19142959","citation_count":18,"is_preprint":false},{"pmid":"15324320","id":"PMC_15324320","title":"TP63 mutation and clefting modifier genes in an EEC syndrome family.","date":"2004","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15324320","citation_count":17,"is_preprint":false},{"pmid":"23463580","id":"PMC_23463580","title":"EEC- and ADULT-associated TP63 mutations exhibit functional heterogeneity toward P63 responsive sequences.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/23463580","citation_count":17,"is_preprint":false},{"pmid":"22310392","id":"PMC_22310392","title":"Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22310392","citation_count":17,"is_preprint":false},{"pmid":"31050217","id":"PMC_31050217","title":"Tooth defects of EEC and AEC syndrome caused by heterozygous TP63 mutations in three Chinese families and genotype-phenotype correlation analyses of TP63-related disorders.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31050217","citation_count":17,"is_preprint":false},{"pmid":"32168425","id":"PMC_32168425","title":"Ozone therapy promotes the differentiation of basal keratinocytes via increasing Tp63-mediated transcription of KRT10 to improve psoriasis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32168425","citation_count":17,"is_preprint":false},{"pmid":"17637751","id":"PMC_17637751","title":"p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and DeltaN isoforms.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17637751","citation_count":16,"is_preprint":false},{"pmid":"22740388","id":"PMC_22740388","title":"A novel de novo missense mutation in TP63 underlying germline mosaicism in AEC syndrome: implications for recurrence risk and prenatal diagnosis.","date":"2012","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/22740388","citation_count":16,"is_preprint":false},{"pmid":"20410354","id":"PMC_20410354","title":"TP63 gene mutations in Chinese P63 syndrome patients.","date":"2010","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/20410354","citation_count":15,"is_preprint":false},{"pmid":"30453078","id":"PMC_30453078","title":"A targeted next-generation gene panel reveals a novel heterozygous nonsense variant in the TP63 gene in patients with arrhythmogenic cardiomyopathy.","date":"2018","source":"Heart rhythm","url":"https://pubmed.ncbi.nlm.nih.gov/30453078","citation_count":14,"is_preprint":false},{"pmid":"32989231","id":"PMC_32989231","title":"miR-184 targets TP63 to block idiopathic pulmonary fibrosis by inhibiting proliferation and epithelial-mesenchymal transition of airway epithelial cells.","date":"2020","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32989231","citation_count":14,"is_preprint":false},{"pmid":"17182369","id":"PMC_17182369","title":"TP63 gene in stress response and carcinogenesis: a broader role than expected.","date":"2006","source":"Bulletin du cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17182369","citation_count":13,"is_preprint":false},{"pmid":"39023169","id":"PMC_39023169","title":"The TDP-43/TP63 Positive Feedback Circuit Promotes Esophageal Squamous Cell Carcinoma Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39023169","citation_count":13,"is_preprint":false},{"pmid":"26890356","id":"PMC_26890356","title":"Repression of Wnt/β-catenin response elements by p63 (TP63).","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26890356","citation_count":13,"is_preprint":false},{"pmid":"21567929","id":"PMC_21567929","title":"Mutation in SAM domain of TP63 is associated with nonsyndromic cleft lip and palate and cleft palate.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21567929","citation_count":12,"is_preprint":false},{"pmid":"29130604","id":"PMC_29130604","title":"Expanding the phenotypic spectrum of TP63-related disorders including the first set of monozygotic twins.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/29130604","citation_count":12,"is_preprint":false},{"pmid":"35480110","id":"PMC_35480110","title":"TGF-β1 Promotes Autophagy and Inhibits Apoptosis in Breast Cancer by Targeting TP63.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35480110","citation_count":11,"is_preprint":false},{"pmid":"32687624","id":"PMC_32687624","title":"SNPs at TP63 gene was specifically associated with right-side cleft lip in Han Chinese population.","date":"2020","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32687624","citation_count":11,"is_preprint":false},{"pmid":"31557339","id":"PMC_31557339","title":"Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing.","date":"2020","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/31557339","citation_count":11,"is_preprint":false},{"pmid":"28849221","id":"PMC_28849221","title":"TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849221","citation_count":11,"is_preprint":false},{"pmid":"17431922","id":"PMC_17431922","title":"EEC syndrome, Arg227Gln TP63 mutation and micturition difficulties: Is there a genotype-phenotype correlation?","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17431922","citation_count":11,"is_preprint":false},{"pmid":"29956121","id":"PMC_29956121","title":"Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk.","date":"2018","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/29956121","citation_count":11,"is_preprint":false},{"pmid":"37729434","id":"PMC_37729434","title":"TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37729434","citation_count":10,"is_preprint":false},{"pmid":"22574117","id":"PMC_22574117","title":"Analysis of large phenotypic variability of EEC and SHFM4 syndromes caused by K193E mutation of the TP63 gene.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22574117","citation_count":10,"is_preprint":false},{"pmid":"31144617","id":"PMC_31144617","title":"NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31144617","citation_count":10,"is_preprint":false},{"pmid":"32993587","id":"PMC_32993587","title":"Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32993587","citation_count":10,"is_preprint":false},{"pmid":"28293528","id":"PMC_28293528","title":"Intermediate Phenotype between ADULT Syndrome and EEC Syndrome Caused by R243Q Mutation in TP63.","date":"2016","source":"Plastic and reconstructive surgery. Global open","url":"https://pubmed.ncbi.nlm.nih.gov/28293528","citation_count":10,"is_preprint":false},{"pmid":"33964467","id":"PMC_33964467","title":"Genetic association scan of 32 osteoarthritis susceptibility genes identified TP63 associated with an endemic osteoarthritis, Kashin-Beck disease.","date":"2021","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/33964467","citation_count":10,"is_preprint":false},{"pmid":"29763931","id":"PMC_29763931","title":"A functional Variant (Rs35592567) in TP63 at 3q28 is Associated with Gastric Cancer Risk via Modifying its Regulation by MicroRNA-140.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29763931","citation_count":10,"is_preprint":false},{"pmid":"25218545","id":"PMC_25218545","title":"Interaction between TP63 and MDM2 genes and the risk of recurrent pregnancy loss.","date":"2014","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/25218545","citation_count":9,"is_preprint":false},{"pmid":"30419764","id":"PMC_30419764","title":"Association Studies Between Regulatory Regions of IRF6/TP63 Genes and Nonsyndromic Oral Clefts.","date":"2018","source":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","url":"https://pubmed.ncbi.nlm.nih.gov/30419764","citation_count":9,"is_preprint":false},{"pmid":"20959455","id":"PMC_20959455","title":"Phosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradation.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20959455","citation_count":9,"is_preprint":false},{"pmid":"27798044","id":"PMC_27798044","title":"Novel mutations in the TP63 gene are potentially associated with Müllerian duct anomalies.","date":"2016","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27798044","citation_count":9,"is_preprint":false},{"pmid":"24893616","id":"PMC_24893616","title":"FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24893616","citation_count":9,"is_preprint":false},{"pmid":"33126320","id":"PMC_33126320","title":"EEC-LM-ADULT syndrome caused by R319H mutation in TP63 with ectrodactyly, syndactyly, and teeth anomaly: A case report.","date":"2020","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33126320","citation_count":9,"is_preprint":false},{"pmid":"23613309","id":"PMC_23613309","title":"Novel mutation in TP63 associated with ectrodactyly ectodermal dysplasia and clefting syndrome and T cell lymphopenia.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/23613309","citation_count":9,"is_preprint":false},{"pmid":"31102921","id":"PMC_31102921","title":"Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women.","date":"2019","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31102921","citation_count":9,"is_preprint":false},{"pmid":"24466311","id":"PMC_24466311","title":"Quantitative assessment of the influence of TP63 gene polymorphisms and lung cancer risk: evidence based on 93,751 subjects.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24466311","citation_count":9,"is_preprint":false},{"pmid":"33906607","id":"PMC_33906607","title":"Uncarboxylated osteocalcin alleviates the inhibitory effect of high glucose on osteogenic differentiation of mouse bone marrow-derived mesenchymal stem cells by regulating TP63.","date":"2021","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33906607","citation_count":9,"is_preprint":false},{"pmid":"22607287","id":"PMC_22607287","title":"ADULT syndrome due to an R243W mutation in TP63.","date":"2012","source":"International journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22607287","citation_count":9,"is_preprint":false},{"pmid":"36389801","id":"PMC_36389801","title":"The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36389801","citation_count":8,"is_preprint":false},{"pmid":"38002937","id":"PMC_38002937","title":"Association between IRF6, TP63, GREM1 Gene Polymorphisms and Non-Syndromic Orofacial Cleft Phenotypes in Vietnamese Population: A Case-Control and Family-Based Study.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38002937","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52202,"output_tokens":8697,"usd":0.143531,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18784,"output_tokens":5997,"usd":0.121923,"stage2_stop_reason":"end_turn"},"total_usd":0.265454,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"TP63 (p73L/KET) encodes a protein with a DNA-binding domain sharing 60.6% identity with p53 and 87.8% identity with p73, placing it as a second p53-related family member; Northern blot analysis showed distinct expression profiles from p73, implying separate tissue-specific roles.\",\n      \"method\": \"Molecular cloning, chromosomal mapping (in situ hybridization), Northern blot analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — molecular cloning with sequence analysis and Northern blot, single lab, foundational characterization\",\n      \"pmids\": [\"9703973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human KET (TP63) maps to chromosome 3q27 between SST and APOD, encodes a 680-amino-acid protein sharing 98% identity with the rat homolog, and is expressed in a pattern consistent with roles in development and differentiation.\",\n      \"method\": \"cDNA cloning, radiation hybrid panel mapping, sequence analysis\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — molecular cloning and mapping, single lab\",\n      \"pmids\": [\"9799841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Multiple KET/p63 splice variants exist; transactivation of the p53-responsive p21 promoter inversely correlated with the length of the N-terminal domain. The amino-terminally truncated ΔNKETα isoform is expressed in epithelial tissues, while the most p53-like isoform TAKETγ is detected in skeletal muscle.\",\n      \"method\": \"RT-PCR cloning of splice variants, luciferase reporter transactivation assay, tissue Northern/RT-PCR analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay plus tissue expression, single lab\",\n      \"pmids\": [\"11470269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A novel isoform ΔNp73L (ΔNp63) is predominantly expressed in squamous cell carcinomas and can inhibit p53- and p51 (TAp63)-mediated transactivation in co-transfection assays, acting as a dominant-negative inhibitor.\",\n      \"method\": \"RT-PCR expression profiling, transient co-transfection reporter assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay and expression analysis, single lab\",\n      \"pmids\": [\"11336476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"An AEC/Rapp-Hodgkin syndrome missense mutation R279H in the TP63 DNA-binding domain disrupts the dominant-negative activity of ΔNp63α and γ isoforms on TP53 transcriptional activity, establishing a functional mechanism for the syndrome.\",\n      \"method\": \"Functional analysis of TP63 mutant isoforms, luciferase reporter assay\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay for dominant-negative function, single lab\",\n      \"pmids\": [\"12939657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TP63 (TAp63 isoforms) transcriptionally activates the MFGE8 (MFG-E8/lactadherin) gene through a p53/p63 response element at –370 bp upstream of the MFGE8 promoter; ΔNp63 enhances this activation when dominant over TAp63 (as in undifferentiated keratinocytes/SCCs). siRNA silencing of p63 in SCC cells decreased MFG-E8 production and reduced Saos-2 cell adhesion.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, tetracycline-inducible expression system, immunohistochemistry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus functional siRNA knockdown, multiple orthogonal methods in one study\",\n      \"pmids\": [\"17637751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In Tp63-deficient mice, facial clefting results from increased Bmp4 signaling in facial process epithelia, which antagonistically reduces Fgf8 and Shh signaling, leading to reduced mesenchymal cell proliferation and increased cell death; thus Tp63 regulates Bmp4 signaling to control facial morphogenesis.\",\n      \"method\": \"Analysis of Tp63 knockout mouse model, signaling molecule expression analysis (Bmp4, Fgf8, Shh), cell proliferation and death assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function mouse model with molecular pathway analysis using multiple readouts\",\n      \"pmids\": [\"18634775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Reciprocal regulatory interactions exist between hedgehog signaling and TP63 in mammary stem/progenitor cells: ΔNp63 and TAp63 are segregated between mammary stem and progenitor fractions respectively; Indian Hedgehog is a binary transcriptional target of TP63; hedgehog signaling promotes differential TP63 promoter usage via disruption of Gli3/Gli3R accumulation, and shRNA knockdown of Gli3 altered TP63 promoter usage and enhanced mammary stem cell clonogenicity.\",\n      \"method\": \"shRNA knockdown, in vivo hedgehog activation, flow cytometry fractionation, promoter usage analysis\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic manipulations in vitro and in vivo, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"18292212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"AEC-syndrome-associated TP63 SAM-domain mutants differentially impair transcriptional induction of the desmosomal protein PERP (a TP63 target critical for cell-cell adhesion), with some but not all AEC mutants showing compromised PERP induction in luciferase reporter assays; skin biopsies from a subset of AEC patients showed aberrant PERP expression.\",\n      \"method\": \"Luciferase reporter assay with AEC TP63 mutants, immunohistochemistry of patient skin biopsies\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay plus patient tissue analysis, single lab\",\n      \"pmids\": [\"19353588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Upon cisplatin treatment, ATM-dependent phosphorylation of ΔNp63α activates it as a transcription factor that binds the RPN13 promoter via a TP63-responsive element, recruits DDIT3 (CHOP), NF-Y, and NF-κB as co-factors, and induces RPN13 transcription, leading to NOS2 degradation; siRNA knockdown of RPN13 rescued NOS2 from cisplatin-dependent inactivation.\",\n      \"method\": \"Chromatin immunoprecipitation, reporter assay, siRNA knockdown, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter assay, siRNA rescue, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"20959455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ΔNp63α expression is regulated by the Wnt/β-catenin pathway through TCF/LEF binding sites in the TP63 P2 promoter; β-catenin and ΔNp63 are co-expressed in esophageal SCC, and activation of this pathway contributes to ΔNp63 overexpression in cancer.\",\n      \"method\": \"Luciferase reporter assay, promoter mutation analysis, immunohistochemistry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay and expression analysis, single lab\",\n      \"pmids\": [\"21643019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AEC-syndrome-causing TP63 mutants impair epidermal differentiation by downregulating ZNF750 and other differentiation activators; ChIP and ChIP-seq demonstrated that wild-type and AEC mutant TP63 directly binds the ZNF750 locus; restoring ZNF750 in AEC organotypic tissue rescued differentiation, establishing ZNF750 as an essential downstream target.\",\n      \"method\": \"ChIP, ChIP-seq, organotypic human epidermal tissue with AEC TP63 mutants, gene rescue experiment\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq plus functional rescue in human organotypic tissue, multiple orthogonal methods\",\n      \"pmids\": [\"22922031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ΔNp63α activates transcription of SUFU (a negative regulator of hedgehog signaling) in keratinocytes, thereby lowering HH pathway activity during differentiation. Loss of SUFU caused deregulation of keratinocyte differentiation and BCL2 overexpression. In vivo murine models also showed GLI-mediated regulation of the TP63 pathway, establishing a reciprocal regulatory node.\",\n      \"method\": \"In vitro reporter assay, in vivo murine models, loss-of-function keratinocyte differentiation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models, multiple readouts, single lab\",\n      \"pmids\": [\"23686138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EEC and ADULT syndrome TP63 mutations in the DNA-binding domain show functional heterogeneity: some mutants (R243W) lose transactivation and gain dominant-negative activity, while others (G173D, G173V, T193_Y194insR) show variable effects dependent on the specific response element tested (including PERP and COL18A1 REs relevant to clinical manifestations); structural modeling supported distinct functional effects.\",\n      \"method\": \"Yeast-based functional assay, mammalian cell transactivation assay, structural modeling of DBD mutations\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — yeast functional assay plus mammalian cell assay plus structural modeling, multiple mutants tested\",\n      \"pmids\": [\"23463580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ChIP-seq analysis revealed that TP53 and TP63 bind overlapping but distinct genomic cistromes using distinctive consensus motifs; in genotoxic stress, TP53 modulates TP63 binding events, resulting in global repression of cell-cycle/DNA-repair genes and activation of anti-proliferative/pro-apoptotic targets. In the absence of genotoxic stress, TP63 maintains expression of DNA repair genes.\",\n      \"method\": \"ChIP-seq integrated with microarray transcriptional analysis, cisplatin and adriamycin treatment\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq plus transcriptomic analysis, multiple conditions tested, mechanistically rigorous\",\n      \"pmids\": [\"24823795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ΔNp63α associates with TCF4 and co-occupies Wnt response elements (WREs) of MMP7 on chromatin, attenuating β-catenin recruitment; this represses WRE-driven transcription including MMP7 in SCC cells. ΔNp63α also appeared to interact with protein phosphatase PP2A, though GSK-3β phosphorylation and β-catenin nuclear localization were not altered by p63 loss.\",\n      \"method\": \"ChIP, co-immunoprecipitation, siRNA knockdown, luciferase reporter assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus co-IP plus reporter assay, multiple methods, single lab\",\n      \"pmids\": [\"26890356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TP63 binds to the super-enhancer at the LINC01503 locus and activates its transcription in squamous cell carcinomas, as demonstrated by ChIP-seq and luciferase reporter assays.\",\n      \"method\": \"ChIP-seq, luciferase reporter assay\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP-seq plus reporter assay, single lab\",\n      \"pmids\": [\"29454790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TP63 and SOX2 cooperatively activate lncRNA CCAT1 expression via its super-enhancers and promoter in SCCs; CCAT1 forms a complex with TP63 and SOX2 (shown by ChIRP analysis) that binds EGFR super-enhancers to activate MEK/ERK1/2 and PI3K/AKT signaling, driving SCC tumorigenesis.\",\n      \"method\": \"ChIRP analysis (chromatin isolation by RNA purification), ChIP-seq, siRNA knockdown, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIRP demonstrating RNA/protein/DNA complex, ChIP-seq, functional knockdown with in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"30190462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TP63 (ΔNp63) expression is sufficient to install and sustain squamous-lineage enhancer landscapes and transcriptional signatures in human pancreatic ductal adenocarcinoma cells, promoting aggressive tumor phenotypes including enhanced motility, invasion, and accelerated tumor growth and metastasis in vivo.\",\n      \"method\": \"Ectopic ΔNp63 expression, enhancer landscape profiling (ChIP-seq), in vivo tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with genome-wide enhancer profiling and in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"30428345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-1β upregulates ΔNP63α specifically through the IL-1β/IL-1RI/β-catenin signaling pathway; elevated ΔNP63α then increases EGFR and Wip1 expression and decreases ATM, contributing to cisplatin resistance; silencing TP63 or inhibiting PI3K/AKT reversed the resistance.\",\n      \"method\": \"Loss-of-function siRNA assays, PI3K/AKT inhibition, Western blot, flow cytometry\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with pharmacological inhibition, multiple cellular readouts, single lab\",\n      \"pmids\": [\"30641908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TP63 binds to transcriptional regulatory regions of ATDC (TRIM29) and KRT14, directly increasing their expression; ATDC and KRT14 execute a TP63-driven invasive program; in vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis.\",\n      \"method\": \"ChIP, reporter assay, shRNA knockdown, in vivo orthotopic tumor model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus in vivo functional validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30643195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wnt/β-catenin signaling in basal cells activates ΔN-TP63, which is necessary and sufficient to mediate Wnt-induced inhibition of epithelial cell specification; this mechanism is conserved across Xenopus, mouse, and human airway basal cells.\",\n      \"method\": \"Loss-of-function and gain-of-function experiments in Xenopus embryos, mouse airway, and human airway basal cell cultures; in vivo Wnt activation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — necessary and sufficient evidence in three independent vertebrate model systems\",\n      \"pmids\": [\"31553905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TP63 directly regulates NRG1 expression in SCC cell lines; squamous tumors are dependent on NRG1 signaling in vivo, and NRG1 inhibition induces keratinization/terminal differentiation, blocking proliferation, identifying NRG1 as a critical TP63 downstream effector.\",\n      \"method\": \"ChIP demonstrating direct TP63 binding to NRG1 locus, genetically engineered mouse models, human xenograft models, NRG1 inhibition\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus in vivo mouse and human xenograft models, multiple orthogonal methods\",\n      \"pmids\": [\"31144617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of TP63 in head and neck squamous epithelia accelerates tumor initiation and promotes HNSCC metastasis; TP63 loss-driven metastasis is mechanistically dependent on MAPK activation, as pharmacologic inhibition of MAPK by trametinib impaired metastasis in TP63 knockdown xenografts.\",\n      \"method\": \"Genetically engineered Trp63 conditional knockout mouse model, orthotopic xenograft assay, MAPK pharmacological inhibition\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mouse model plus pharmacological epistasis in vivo, multiple orthogonal approaches\",\n      \"pmids\": [\"30910837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TP63 (ΔNp63α) acts as a pioneer transcription factor that binds closed chromatin, enhances chromatin accessibility at epidermal enhancers, coordinates chromatin-remodeling enzymes to orchestrate tissue-specific enhancer landscapes and 3D chromatin architecture; in SCCs it establishes squamous-like enhancer landscapes to drive oncogenic target expression.\",\n      \"method\": \"ATAC-seq, ChIP-seq, Hi-C/chromosome conformation capture, chromatin remodeling enzyme co-immunoprecipitation (reviewed/synthesized from multiple studies)\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing multiple experimental approaches; accepted as established based on cited primary work\",\n      \"pmids\": [\"32447427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TP63, SOX2, and KLF5 form a core regulatory circuitry in ESCC cells that determines chromatin accessibility and gene expression; direct interactions between the TP63 promoter and distal functional enhancers were verified by circular chromosome conformation capture; knockdown of any one factor reduces viability; super-enhancer regulation of ALDH3A1 mediated by this circuitry is required for ESCC viability.\",\n      \"method\": \"ChIP-seq, ATAC-seq, circular chromosome conformation capture sequencing (4C-seq), CRISPR/Cas9 enhancer deletion, shRNA knockdown, xenograft tumor assays\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genome-wide approaches plus CRISPR functional validation and in vivo confirmation\",\n      \"pmids\": [\"32619460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tp63 deletion by CRISPR/Cas9 in ES cells halted basal (TP63+/KRT5+) and airway epithelial cell differentiation on decellularized lung scaffolds, demonstrating that TP63 is indispensable for endoderm-to-proximal airway differentiation via basal cell intermediates.\",\n      \"method\": \"CRISPR/Cas9 gene deletion in ES cells, decellularized lung scaffold recellularization assay, immunostaining\",\n      \"journal\": \"NPJ Regenerative medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — CRISPR loss-of-function with defined differentiation readout, single lab\",\n      \"pmids\": [\"33674599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tp63-expressing epithelial stem cells from non-skin organs (cornea, oesophagus, vagina, bladder, prostate) can respond to skin morphogenetic signals and contribute to hair follicles and epidermis renewal in vivo, demonstrating that Tp63 expression confers latent skin (epidermal lineage) competence to diverse epithelial stem cells.\",\n      \"method\": \"Transplantation of non-skin Tp63+ epithelial stem cells into newborn skin microenvironment, lineage tracing, immunostaining\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transplantation with lineage marker readout, single lab but multiple cell types tested\",\n      \"pmids\": [\"33159086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DLX5 cooperates with TP63 to co-regulate approximately 2000 enhancers and promoters converging on cancer-promoting pathways in SCCs; DLX5 promoter activation in ESCC is directly mediated by SOX2 (distinct from TP63-driven regulation).\",\n      \"method\": \"ChIP-seq, epigenomic profiling, siRNA knockdown, in vitro and in vivo viability assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq demonstrating co-occupancy plus functional knockdown, single lab\",\n      \"pmids\": [\"34370013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TP63 missense variants that disrupt the C-terminal transactivation-inhibitory domain (TID) cause constitutive p63 tetramer formation and constitutive transcriptional activation (demonstrated by blue-native PAGE and luciferase reporter assays), leading to premature ovarian insufficiency by promoting oocyte apoptosis.\",\n      \"method\": \"Blue-native PAGE, luciferase reporter assay, functional characterization of patient-derived variants\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — two orthogonal biochemical methods (native PAGE + reporter) demonstrating constitutive activation mechanism, single lab\",\n      \"pmids\": [\"35801529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TP63 gain-of-function mutations impairing the TID cause constitutive TAp63α tetramer formation and activation, inducing oocyte apoptosis through increased expression of apoptosis-inducing factors; knock-in mice with p63+/ΔTID or p63+/R647C showed rapid oocyte depletion via apoptosis, confirming the mechanism of POI.\",\n      \"method\": \"In vitro functional assay of mutant protein activity, CRISPR knock-in mouse models (p63+/ΔTID and p63+/R647C), oocyte counting, apoptosis assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro mechanistic assay corroborated by two independent knock-in mouse models with defined cellular phenotype\",\n      \"pmids\": [\"36856110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TP63 fusions (e.g., TBL1XR1::TP63) act as oncogenes; they coordinate recruitment of two epigenetic complexes — NCoR-HDAC3 (via the N-terminal fusion partner) and KMT2D (via the C-terminal TP63 component) — at enhancers, driving a cell state with upregulation of MYC, EED, and EZH2. EZH2 inhibition with valemetostat is highly effective in TP63 fusion-positive lymphoma models and in a patient.\",\n      \"method\": \"Transgenic mouse models, ChIP-seq, co-immunoprecipitation of epigenetic complexes, xenograft models, patient-derived xenografts, clinical case\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic dissection using transgenic mice, co-IP of specific complexes, genome-wide ChIP-seq, multiple model systems, and clinical validation\",\n      \"pmids\": [\"37729434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"YAP/TAZ, TEAD, and TP63 form a converged transcriptional complex in bronchial epithelial cells that cooperatively promotes basal cell proliferation and represses immune/interferon responses (including repression of MHC Class II transactivator CIITA), as defined by combined ChIP-seq and siRNA depletion RNA-seq experiments.\",\n      \"method\": \"ChIP-seq, siRNA depletion followed by RNA-seq, integration with human premalignant lesion gene expression data\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq co-occupancy plus RNA-seq after depletion, single lab, human primary cells\",\n      \"pmids\": [\"37150829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TP63 and STAT1 mutually suppress each other at the transcriptional level by co-occupying and co-regulating each other's promoters and enhancers; TP63 inhibition leads to increased IFNγ signaling, enhanced CD8+ T cell infiltration, and increased tumor killing in syngeneic mouse models and ex vivo co-culture systems, and TP63 silencing enhances efficacy of PD-1 blockade.\",\n      \"method\": \"ChIP-seq (co-occupancy), syngeneic mouse tumor models, ex vivo co-culture T cell killing assay, siRNA knockdown, combinatorial immunotherapy experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal ChIP-seq demonstrating mutual promoter co-occupancy plus in vivo functional validation in multiple systems\",\n      \"pmids\": [\"38509096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TDP-43 post-transcriptionally stabilizes TP63 mRNAs (as an RNA-binding protein) and also transcriptionally activates TP63 by binding its promoter; reciprocally, TP63 binds the TDP-43 promoter to activate TDP-43 transcription, forming a positive feedback circuit in ESCC cells.\",\n      \"method\": \"RNA-binding assays, ChIP/promoter binding assays, RNA stability assays, knockdown/overexpression experiments\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional promoter binding and RNA stabilization shown by multiple methods, single lab\",\n      \"pmids\": [\"39023169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCR stimulation induces p63 protein expression in aggressive CLL subset #8 and promotes CLL cell survival; siRNA-mediated downregulation of p63 increased apoptosis in subset #8 cells, establishing p63 as a pro-survival factor in this CLL subset.\",\n      \"method\": \"BCR stimulation assay, siRNA knockdown, apoptosis assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA knockdown with apoptosis readout, single lab\",\n      \"pmids\": [\"30447004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A missense variant (V405M) in the TP63 oligomerization domain found in patients with orofacial clefting abrogates oligomerization of mutant p63 protein into oligomeric complexes, indicating loss-of-function rather than dominant-negative mechanism, and supporting dosage-dependent functions of p63.\",\n      \"method\": \"Biochemical oligomerization assay of patient-derived variant protein\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct biochemical oligomerization assay, single lab, single variant\",\n      \"pmids\": [\"30850703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ozone treatment promotes Tp63-mediated transcription of KRT10 in basal keratinocytes; Tp63 was shown by ChIP to directly bind the KRT10 promoter; silencing Tp63 reversed ozone-induced KRT10 upregulation and keratinocyte differentiation.\",\n      \"method\": \"ChIP, siRNA knockdown, RT-PCR, Western blot, in vivo psoriasis mouse model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus siRNA knockdown, multiple readouts, single lab\",\n      \"pmids\": [\"32168425\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TP63 encodes a family of transcription factor isoforms (TAp63 and ΔNp63, with multiple C-terminal variants) that act as master regulators of stratified epithelial identity: ΔNp63α functions as a pioneer factor binding closed chromatin to establish squamous/epidermal enhancer landscapes by recruiting chromatin remodelers, activates oncogenic targets (NRG1, CCAT1, ATDC, MFG-E8, KRT10) and represses IFNγ/STAT1 signaling to promote immune evasion, while TAp63α guards oocyte genome integrity by forming constitutively active tetramers upon TID disruption to drive apoptosis; isoform-specific activities are regulated by ATM-dependent phosphorylation, Wnt/β-catenin pathway input, reciprocal hedgehog/GLI3 signaling, and miRNA-mediated post-transcriptional control, with dominant-negative ΔNp63 isoforms suppressing both TAp63 and TP53 transcriptional activities, and TP63 fusion oncoproteins coordinating NCoR-HDAC3 and KMT2D epigenetic complexes to rewire enhancers in lymphoma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TP63 is a p53/p73-related transcription factor family whose isoforms (TAp63 and the N-terminally truncated ΔNp63, each with multiple C-terminal variants) act as master regulators of stratified epithelial identity and oocyte genome surveillance [#0, #2, #3]. ΔNp63α functions as a pioneer factor that binds closed chromatin, increases accessibility at epidermal enhancers, and coordinates chromatin remodelers to establish tissue-specific enhancer landscapes and 3D genome architecture [#24]; it is necessary and sufficient to install squamous-lineage enhancer programs, and ectopic ΔNp63 imposes a squamous transcriptional state on non-squamous tumor cells [#18]. In epithelia it directs differentiation by directly activating targets including ZNF750, PERP, MFG-E8, and KRT10/KRT14 [#11, #9, #5, #37, #20], while in squamous cancers it operates within core regulatory circuitries with SOX2, KLF5, DLX5, and YAP/TAZ-TEAD to drive oncogenic targets such as NRG1, ATDC/TRIM29, LINC01503, and the lncRNA CCAT1 [#25, #28, #32, #22, #20, #16, #17]. TP63 promotes immune evasion by reciprocally repressing STAT1 and IFNγ signaling, and its loss enhances CD8+ T cell killing and PD-1 blockade efficacy [#33, #32]. Its activity is tuned by ATM-dependent phosphorylation, Wnt/β-catenin input through TCF/LEF sites and TCF4 association, and reciprocal hedgehog/GLI signaling [#9, #11, #21, #15, #7, #12]. ΔNp63 isoforms exert dominant-negative suppression of TAp63- and TP53-mediated transactivation, a function disrupted by syndromic DNA-binding-domain mutations [#3, #4]. In the female germline, TAp63α is held inactive by its C-terminal transactivation-inhibitory domain (TID); variants that disrupt the TID drive constitutive tetramer formation and transcriptional activation, causing oocyte apoptosis and premature ovarian insufficiency [#29, #30]. TP63 fusion oncoproteins (e.g., TBL1XR1::TP63) coordinate NCoR-HDAC3 and KMT2D complexes at enhancers to drive a MYC/EZH2 cell state in lymphoma [#31]. TP63 mutations cause AEC/Rapp-Hodgkin, EEC, and ADULT ectodermal dysplasia syndromes and orofacial clefting through impaired transactivation, dominant-negative gain, or loss of oligomerization [#4, #13, #11, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established TP63 as a third p53-family member, raising the question of whether it had distinct, tissue-specific functions from p53 and p73.\",\n      \"evidence\": \"Molecular cloning, chromosomal mapping to 3q27, and Northern blot expression profiling\",\n      \"pmids\": [\"9703973\", \"9799841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional transcriptional readout in original cloning\", \"Isoform diversity not yet resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the isoform architecture, showing that N-terminal truncation (ΔNp63) inverts transactivation potential and that ΔN isoforms act as dominant-negative inhibitors of p53/TAp63, framing TP63 as a bifunctional locus.\",\n      \"evidence\": \"RT-PCR splice-variant cloning, luciferase reporter transactivation assays, tissue expression analysis\",\n      \"pmids\": [\"11470269\", \"11336476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous target genes not identified\", \"Mechanism of dominant-negative inhibition (heterotetramerization vs promoter competition) not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Linked TP63 dysfunction directly to human ectodermal dysplasia by showing an AEC/Rapp-Hodgkin DBD mutation disrupts ΔNp63 dominant-negative activity on TP53.\",\n      \"evidence\": \"Functional analysis of patient mutant isoforms in luciferase reporter assays\",\n      \"pmids\": [\"12939657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between altered TP53 regulation and skin phenotype indirect\", \"Genome-wide consequences not assessed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided the first ChIP-validated direct target (MFGE8), establishing TP63 as a sequence-specific activator influencing cell adhesion and demonstrating isoform-context-dependent activation.\",\n      \"evidence\": \"ChIP, luciferase reporter, siRNA knockdown, inducible expression, IHC\",\n      \"pmids\": [\"17637751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single target locus\", \"Genome-wide cistrome not yet defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed TP63 within developmental signaling networks, showing it controls facial morphogenesis through Bmp4/Fgf8/Shh and engages reciprocal hedgehog/GLI3 regulation in epithelial stem/progenitor compartments.\",\n      \"evidence\": \"Tp63 knockout mouse pathway analysis; shRNA Gli3 knockdown and in vivo hedgehog activation in mammary fractions\",\n      \"pmids\": [\"18634775\", \"18292212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect regulation of signaling ligands not fully separated\", \"Isoform-specific contributions in vivo incompletely defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined upstream regulation of TP63 by genotoxic stress (ATM-dependent phosphorylation of ΔNp63α activating RPN13/NOS2 axis) and environmental input (ozone-driven KRT10 induction), connecting signaling to specific transcriptional outputs.\",\n      \"evidence\": \"ChIP, reporter assays, siRNA rescue, Western blot; in vivo psoriasis model for KRT10\",\n      \"pmids\": [\"20959455\", \"32168425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosite-to-DNA-binding mechanism not structurally resolved\", \"Breadth of stress-responsive cistrome unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified Wnt/β-catenin as a driver of ΔNp63 overexpression in cancer via TCF/LEF sites in the P2 promoter, and later showed ΔNp63α reciprocally restrains β-catenin/TCF4 transcription on chromatin.\",\n      \"evidence\": \"Reporter and promoter-mutation assays, IHC; ChIP and co-IP with TCF4/PP2A at WREs\",\n      \"pmids\": [\"21643019\", \"26890356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PP2A interaction functional consequence unresolved\", \"GSK-3β/β-catenin localization unchanged, leaving mechanism of WRE repression incomplete\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established ZNF750 as an essential differentiation effector downstream of TP63 and demonstrated AEC mutants act through failed activation of differentiation genes.\",\n      \"evidence\": \"ChIP-seq plus functional ZNF750 rescue in AEC organotypic human epidermis\",\n      \"pmids\": [\"22922031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of differentiation targets not enumerated\", \"Why some loci escape mutant binding unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved the functional heterogeneity of syndromic TP63 mutations (DBD and SAM-domain) and defined a SUFU-mediated negative feedback onto hedgehog signaling during keratinocyte differentiation.\",\n      \"evidence\": \"Yeast and mammalian transactivation assays, structural modeling; reporter and loss-of-function keratinocyte assays with in vivo GLI models\",\n      \"pmids\": [\"23463580\", \"19353588\", \"23686138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Response-element-specific effects not mapped genome-wide\", \"Quantitative genotype-phenotype correlation incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the TP63 cistrome relative to TP53, showing overlapping but distinct binding and that TP63 maintains DNA-repair gene expression while TP53 redirects TP63 binding under genotoxic stress.\",\n      \"evidence\": \"ChIP-seq integrated with microarray after cisplatin/adriamycin treatment\",\n      \"pmids\": [\"24823795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform-specific cistromes not separated\", \"Mechanism of TP53-directed TP63 redistribution unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established ΔNp63 as a pioneer/lineage-installing factor and a hub of squamous core regulatory circuitry driving oncogenic enhancer programs and lncRNAs (LINC01503, CCAT1).\",\n      \"evidence\": \"ChIP-seq, ChIRP, ectopic ΔNp63 expression with enhancer profiling, in vivo tumor models\",\n      \"pmids\": [\"29454790\", \"30190462\", \"30428345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin remodelers recruited not fully enumerated in these studies\", \"Reversibility of installed enhancer states untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined direct oncogenic effectors (NRG1, ATDC/TRIM29, KRT14) and the context-dependent dual role of TP63, where ΔNp63 promotes invasion in some squamous settings while TP63 loss accelerates HNSCC metastasis via MAPK; also linked Wnt-ΔNp63 to airway basal cell specification and IL-1β/β-catenin to cisplatin resistance.\",\n      \"evidence\": \"ChIP, GEMMs, xenografts, MAPK inhibition, multi-species LOF/GOF, siRNA with PI3K/AKT inhibition; BCR-induced survival in CLL\",\n      \"pmids\": [\"31144617\", \"30643195\", \"30910837\", \"31553905\", \"30641908\", \"30447004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of pro- vs anti-tumor outcome of TP63 not mechanistically unified\", \"Isoform identity in metastasis-suppressive contexts not always defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Consolidated the pioneer-factor model and core squamous circuitry (TP63-SOX2-KLF5) controlling chromatin accessibility, super-enhancers, and viability, and demonstrated TP63 is indispensable for airway basal cell differentiation and confers epidermal competence to diverse epithelial stem cells.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, Hi-C/4C-seq, CRISPR enhancer deletion, CRISPR ES-cell deletion on lung scaffolds, in vivo stem-cell transplantation\",\n      \"pmids\": [\"32447427\", \"32619460\", \"33674599\", \"33159086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical interactions with specific remodelers not all reconstituted\", \"Hierarchy among circuitry members not fully ordered\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the germline-protective mechanism: the C-terminal TID keeps TAp63α as an inactive dimer, and TID-disrupting variants force constitutive tetramerization and activation, causing premature ovarian insufficiency through oocyte apoptosis.\",\n      \"evidence\": \"Blue-native PAGE, luciferase reporters, patient-variant characterization; CRISPR knock-in mice (ΔTID, R647C) with oocyte counting and apoptosis assays\",\n      \"pmids\": [\"35801529\", \"36856110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro-apoptotic target genes only partially defined\", \"Physiological TID-disruption trigger in normal oocytes not detailed here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed TP63 fusion oncoproteins as enhancer-rewiring agents recruiting NCoR-HDAC3 and KMT2D to drive MYC/EZH2 states, and defined a YAP/TAZ-TEAD-TP63 complex coupling basal proliferation to immune/interferon repression.\",\n      \"evidence\": \"Transgenic mice, ChIP-seq, co-IP of epigenetic complexes, PDX with EZH2 inhibition and clinical case; ChIP-seq plus depletion RNA-seq in bronchial cells\",\n      \"pmids\": [\"37729434\", \"37150829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of fusion mechanism across partners untested\", \"Stoichiometry and assembly order of YAP/TAZ-TEAD-TP63 complex unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established TP63 as a driver of immune evasion through mutual transcriptional repression with STAT1, and identified a TDP-43 positive-feedback circuit stabilizing and transcribing TP63, defining therapeutic intersections with immunotherapy.\",\n      \"evidence\": \"Reciprocal ChIP-seq, syngeneic tumor models, ex vivo T-cell killing, PD-1 combination; RNA-binding, promoter-binding, and RNA-stability assays\",\n      \"pmids\": [\"38509096\", \"39023169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical basis of TP63-STAT1 mutual repression at shared elements not fully dissected\", \"Isoform responsible for STAT1 repression not specified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct isoform-specific cistromes, post-translational regulation, and partner complexes are integrated to switch TP63 between epithelial-differentiation, oncogenic, germline-apoptotic, and immune-repressive programs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking isoform balance to opposing tumor-promoting vs tumor-suppressive outcomes\", \"Structural basis of pioneer-factor closed-chromatin engagement not defined in corpus\", \"Comprehensive remodeler/chaperone interactome not biochemically reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 3, 5, 11, 14, 24, 25, 30]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 11, 14, 24, 25, 37]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 9, 14, 24, 29]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [24, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 11, 14, 24, 25]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [24, 25, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 21, 26, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 13, 29, 30, 31, 36]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [29, 30, 35]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 11, 12, 19, 21, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [32, 33]}\n    ],\n    \"complexes\": [\n      \"TP63-SOX2-KLF5 core regulatory circuitry\",\n      \"YAP/TAZ-TEAD-TP63 transcriptional complex\",\n      \"TP63-SOX2-CCAT1 ribonucleoprotein complex\",\n      \"TP63 fusion (TBL1XR1::TP63) NCoR-HDAC3/KMT2D enhancer complex\"\n    ],\n    \"partners\": [\"SOX2\", \"KLF5\", \"DLX5\", \"TCF4\", \"TP53\", \"STAT1\", \"TDP-43\", \"KMT2D\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}